Analyst firms · BTIG · NKTR
BTIG NKTR price target and rating history
Nektar Therapeutics (NKTR) · Health Care
BTIG rates Nektar Therapeutics (NKTR) Buy with a $100 price target, as of its latest action on Jun 24, 2025. It has published 3 rating actions on NKTR since March 2022, including 0 upgrades and 1 downgrade. Across 5 firms with a NKTR price target in the last 12 months, the median target is $102.
- Current rating
- Buy
- Price target
- $100
- Median target, all firms
- $102
- Actions on NKTR
- 3
BTIG price target on NKTR
Every BTIG rating on NKTR
- Jun 24, 2025
- Sep 30, 2024
- Mar 14, 2022DowngradeBTIG downgrades to Neutral from Buy
How other firms rate NKTR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $53 | Oct 12, 2026 |
| Leerink Partners | Outperform | $130 | Oct 12, 2026 |
| Raymond James | Mkt Perform | Oct 9, 2026 | |
| Canaccord Genuity | Buy | $153 | Jul 22, 2026 |
| Wedbush | Neutral | $70 | Mar 24, 2026 |
| TD Cowen | Buy | Mar 17, 2026 | |
| William Blair | Outperform | Feb 10, 2026 | |
| Citigroup | Buy | $102 | Nov 26, 2025 |
Questions about BTIG and NKTR
- What is BTIG's price target for NKTR?
- BTIG's latest stated price target for Nektar Therapeutics (NKTR) is $100, from its action on Jun 24, 2025.
- What is BTIG's rating on NKTR?
- BTIG rates NKTR Buy, a bullish rating, as of Jun 24, 2025.
- When did BTIG last change its view on NKTR?
- On Jun 24, 2025, BTIG raises its price target to $100 from $60, keeps Buy.
- How does BTIG's NKTR target compare with other analysts?
- Across 5 firms with a NKTR price target in the last 12 months, the median target is $102.
More NKTR rating histories
All BTIG ratingsNKTR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.